– USA, CA – NovaBay® Pharmaceuticals, Inc. (NYSE: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, today announced that Jeff Zheng, Ph.D. has joined the Company’s board as an independent director. Dr. Zheng will chair the nominating and corporate governance committee and will serve on the audit and compensation committees. He replaces Todd Zavodnick, who has resigned from the NovaBay board.
“Jeff brings us extensive corporate governance and financial experience that includes a track record of providing innovative corporate financing solutions from his many years in an advisory capacity to microcap companies. We expect to call upon this broad expertise as we continue to focus on cost-effectively growing Avenova sales,” said Paul E. Freiman, NovaBay’s Chairman.
“We are grateful for Todd’s contributions to the NovaBay board over the past two years,” he added.
“This is an exciting time at NovaBay following the successful completion of financings in June and August. We are now putting that money to good use by developing new online marketing initiatives to promote Avenova Direct,” said Justin Hall, NovaBay president and CEO. “We launched our direct-to-consumer sales channel in June and see this as our most promising growth opportunity. We are delighted to welcome Dr. Zheng to our board and look forward to his guidance.”
Dr. Zheng previously was a financial advisor for various Canadian public companies including P&P Ventures Inc. (TSX-V: PPV.H), where he served as President and a director; Damon Capital Corp (TSX-V: DAM.H), where he was Chief Financial Officer and a director; and Cantronic Systems Inc. (TSX-V: CTS), where he served as a director and chair of the audit committee. Dr. Zheng received a Ph.D. in physics from Flinders University of South Australia.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for the wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.